Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2984179 | 0.95 | CYP1A2 (0.44) | CYP1A2CYP2C19NPC1LMNAHTT | |
| SCHEMBL2975545 | 0.88 | CYP1A2 (0.55) | CYP1A2CYP2C19NPC1LMNAHTT | |
| SCHEMBL4070157 | 0.81 | CA5A (0.61) | FDPSNPC1LMNAHTTPPARA | |
| SCHEMBL13250648 | 0.79 | FDPS (0.49) | CYP2C19FDPSNPC1PPARAMEN1 | |
| SCHEMBL4189413 | 0.76 | FDPS (0.54) | FDPSLMNAHSD17B10MEN1KMT2A | |
| SCHEMBL2987951 | 0.74 | NPSR1 (0.48) | CYP1A2CYP2C19NPC1LMNAHTT | |
| SCHEMBL2928634 | 0.74 | ALOX5 (0.55) | CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL30859524 | 0.74 | LMNA (0.63) | NPC1LMNAHTTMEN1KMT2A | |
| SCHEMBL11187045 | 0.74 | LMNA (0.63) | NPC1LMNAHTTMEN1KMT2A | |
| SCHEMBL1050659 | 0.73 | FDPS (0.41) | FDPSNPC1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027093-A2 | SUBSTITUTED CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007146323-A2 | SUBSTITUTED CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | WYETH | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K6 | CYP1A2 2205/4885CYP2C19 3151/4885FDPS 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.